Sugi Predict

Sugi Predict / Compounds / SCHEMBL4378996

SCHEMBL4378996

SCHEMBL4378996

N#Cc1cccc(C2CO2)c1

nearest known ligand 0.50

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ DRD2 P14416 8/20 0.50
▸ DRD3 P35462 8/20 0.50
▸ TSHR P16473 2/20 0.48
▸ CYP19A1 P11511 1/20 0.47
▸ PARP1 P09874 1/20 0.46
▸ LDHA P00338 1/20 0.42
▸ ABCC9 O60706 1/20 0.42
▸ ABCC8 Q09428 1/20 0.42
▸ KCNJ11 Q14654 1/20 0.42
▸ KCNJ8 Q15842 1/20 0.42
▸ CYP2D6 P10635 1/20 0.41
▸ NFKB1 P19838 1/20 0.41
▸ CASP1 P29466 1/20 0.41
▸ NPSR1 Q6W5P4 1/20 0.40
▸ ENPP2 Q13822 1/20 0.40
▸ KDM1A O60341 1/20 0.40
▸ MAOA P21397 1/20 0.40
▸ MAOB P27338 1/20 0.40
▸ USP30 Q70CQ3 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16412900 1.00 DRD2 (0.50) DRD2DRD3TSHRCYP19A1PARP1
SCHEMBL29813085 1.00 DRD2 (0.50) DRD2DRD3TSHRCYP19A1PARP1
SCHEMBL6540021 1.00 DRD2 (0.50) DRD2DRD3TSHRCYP19A1PARP1
SCHEMBL4697941 0.88 DRD2 (0.44) DRD2DRD3TSHRCYP19A1PARP1
SCHEMBL4698144 0.87 DRD2 (0.43) DRD2DRD3TSHRCYP19A1LDHA
SCHEMBL31332598 0.85 DRD2 (0.51) DRD2DRD3TSHRCYP19A1LDHA
SCHEMBL4699085 0.81 DRD2 (0.51) DRD2DRD3TSHRCYP19A1ABCC9
SCHEMBL8234528 0.81 DRD2 (0.44) DRD2DRD3TSHRCYP19A1LDHA
SCHEMBL14745935 0.80 DRD2 (0.54) DRD2DRD3CYP19A1ABCC9ABCC8
SCHEMBL4697009 0.80 DRD2 (0.50) DRD2DRD3TSHRCYP19A1ABCC9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4294800-B1 APOL1 INHIBITORS AND METHODS OF USE MAZE THERAPEUTICS INC (US) 2026-05-06 — — EP disclosed
US-20260055083-A1 APOL1 INHIBITORS AND METHODS OF USE MAZE THERAPEUTICS INC (US) 2026-02-26 — — US disclosed
US-20260042758-A1 AZAINDOLE DERIVATIVES AND THEIR USE AS ERK KINASE INHIBITORS AGV DISCOVERY (FR) 2026-02-12 — — US disclosed
EP-4573077-A1 APOL1 INHIBITORS AND METHODS OF USE Maze Therapeutics, Inc. (US) 2025-06-25 — — EP disclosed
WO-2024249252-A1 METHODS OF USING APOL1 INHIBITORS MAZE THERAPEUTICS, INC. (US) 2024-12-05 — — WO disclosed
EP-4463453-A1 AZAINDOLE DERIVATIVES AND THEIR USE AS ERK KINASE INHIBITORS AGV Discovery (FR) 2024-11-20 — — EP disclosed
US-20240316038-A1 APOL1 INHIBITORS AND METHODS OF USE HERCULES CAPITAL, INC., AS AGENT 2024-09-26 — — US disclosed
US-20240308997-A1 AZAINDOLE DERIVATIVES AND THEIR USE AS ERK KINASE INHIBITORS AGV DISCOVERY (FR) 2024-09-19 — — US disclosed
WO-2024040235-A1 APOL1 INHIBITORS AND METHODS OF USE MAZE THERAPEUTICS, INC. (US) 2024-02-22 — — WO disclosed
EP-4294800-A1 APOL1 INHIBITORS AND METHODS OF USE Maze Therapeutics, Inc. (US) 2023-12-27 — — EP disclosed
EP-1389185-A2 AMINOALCOHOL DERIVATIVES FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2004-02-18 — — EP disclosed
US-6673793-B2 N-(4-CHLOROBENZYL)-9-(MORPHOLIN-4-YLMETHYL)-7-OXO-2-(S)-PYRIDIN-2-YL-2,3-DIHYDRO-7H-(1,4) OXAZINO(2,3,4-IJ)QUINOLINE-6-CARBOXAMIDE, FOR EXAMPLE; INHIBITING A VIRAL DNA POLYMERASE; TREATING VIRUSES OF HERPES FAMILY PHARMACIA & UPJOHN CO. 2004-01-06 — — US disclosed
EP-1299395-A1 OXAZINOQUINOLONES USEFUL FOR THE TREATMENT OF VIRAL INFECTIONS PHARMACIA & UPJOHN COMPANY (US) 2003-04-09 — — EP disclosed
WO-2002094770-A2 AMINOALCOHOL DERIVATIVES FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2002-11-28 — — WO disclosed
US-20020103170-A1 Oxazinoquinolones useful for the treatment of viral infections PHARMACIA & UPJOHN COMPANY 2002-08-01 — — US disclosed
WO-2002004462-A1 OXAZINOQUINOLONES USEFUL FOR THE TREATMENT OF VIRAL INFECTIONS PHARMACIA & UPJOHN COMPANY (US) 2002-01-17 — — WO disclosed
EP-0757674-A1 SUBSTITUTED SULFONAMIDES AS SELECTIVE $g(b) 3? AGONISTS FOR THE TREATMENT OF DIABETES AND OBESITY Merck & Co., Inc. (US) 1997-02-12 — — EP disclosed
US-5561142-A Substituted sulfonamides as selective β3 agonists for the treatment of diabetes and obesity MERCK & CO., INC. (US) 1996-10-01 — — US disclosed
US-5541197-A Substituted sulfonamides as selective β3 agonists for the treatment of diabetes and obesity MERCK & CO., INC. (US) 1996-07-30 — — US disclosed
WO-1995029159-A1 SUBSTITUTED SULFONAMIDES AS SELECTIVE β3 AGONISTS FOR THE TREATMENT OF DIABETES AND OBESITY MERCK & CO., INC. (US) 1995-11-02 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260042758-A1 AZAINDOLE DERIVATIVES AND THEIR USE AS ERK KINASE INHIBITORS BRAF, RAF1, NRAS DRD2 2482/4885DRD3 2717/4885TSHR 929/4885
US-20260055083-A1 APOL1 INHIBITORS AND METHODS OF USE APOL1, LDLR, APOB DRD2 4337/4885DRD3 3210/4885TSHR 1084/4885
US-20020103170-A1 Oxazinoquinolones useful for the treatment of viral infections ZC3HAV1, RPL5, ZC3HAV1L DRD2 4832/4885DRD3 4806/4885TSHR 4826/4885
US-20240316038-A1 APOL1 INHIBITORS AND METHODS OF USE APOL1, SAAL1, APOB DRD2 4576/4885DRD3 3903/4885TSHR 2856/4885
US-20240308997-A1 AZAINDOLE DERIVATIVES AND THEIR USE AS ERK KINASE INHIBITORS MAPKAPK2, MAPK1, MAPK7 DRD2 1476/4885DRD3 1774/4885TSHR 2181/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.